dronabinol has been researched along with Allergic Encephalomyelitis in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Atamas, SP; Boffa, L; Chintalacharuvu, SR; Chiurchiù, V; Evron, T; Mercuri, NB; Saracini, S; Tiberi, M | 1 |
| Al-Ghezi, ZZ; Miranda, K; Nagarkatti, M; Nagarkatti, PS | 1 |
| Al-Ghezi, ZZ; Alghetaa, H; Busbee, PB; Nagarkatti, M; Nagarkatti, PS | 1 |
| Ben-Nun, A; Juknat, A; Kaushansky, N; Kozela, E; Rimmerman, N; Vogel, Z | 1 |
| Baker, D; Giovannoni, G; Pryce, G; Riddall, DR; Selwood, DL | 1 |
| Carrillo-Salinas, FJ; de Lago, E; Espejo-Porras, F; Feliú, A; Fernández-Ruiz, J; Guaza, C; Mecha, M; Moreno-Martet, M | 1 |
| Bernardi, G; Cantarella, C; Cavasinni, F; Centonze, D; De Chiara, V; Furlan, R; Lo Giudice, T; Martino, G; Martorana, A; Mataluni, G; Musella, A; Muzio, L; Rossi, S | 1 |
| Bernardi, G; Cavasinni, F; Centonze, D; Cravatt, BF; De Chiara, V; Furlan, R; Lutz, B; Maccarrone, M; Martino, G; Motta, C; Musella, A; Muzio, L; Rossi, S; Studer, V | 1 |
| Egashira, N; Fujiwara, M | 1 |
| Bari, M; Battistini, L; Bernardi, G; Bernardini, S; Centonze, D; De Chiara, V; Fezza, F; Furlan, R; Maccarrone, M; Martino, G; Prosperetti, C; Rossi, S | 1 |
| Achiron, A; Biegon, A; Lavie, V; Margalit, R; Miron, S | 1 |
| Lyman, WD | 1 |
| Bornstein, MB; Brosnan, CF; Elkin, R; Lyman, WD; Sonett, JR | 1 |
3 review(s) available for dronabinol and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids.
Topics: Animals; Cannabinoids; Cannabis; Dose-Response Relationship, Drug; Dronabinol; Encephalomyelitis, Autoimmune, Experimental; Humans; Medical Marijuana; Mice; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents | 2015 |
New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application.
Topics: Animals; Behavior, Animal; Dronabinol; Encephalomyelitis, Autoimmune, Experimental; Glutamic Acid; Humans; Memory Disorders; Receptor, Cannabinoid, CB1 | 2004 |
Drugs of abuse and experimental autoimmune diseases.
Topics: Animals; Autoimmune Diseases; Demyelinating Diseases; Disease Models, Animal; Dronabinol; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental; Female; Immunosuppressive Agents; Lymphocyte Activation; Male; Multiple Sclerosis; Neuritis, Autoimmune, Experimental; Polyradiculoneuropathy; Rats; Rats, Inbred Lew | 1991 |
10 other study(ies) available for dronabinol and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Potent T cell-mediated anti-inflammatory role of the selective CB2 agonist lenabasum in multiple sclerosis.
Topics: Adult; Animals; Anti-Inflammatory Agents; Apoptosis; Cannabinoid Receptor Agonists; Cell Survival; Dronabinol; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Male; Mice; Multiple Sclerosis, Relapsing-Remitting; Receptor, Cannabinoid, CB2; T-Lymphocyte Subsets | 2022 |
Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways.
Topics: Animals; Anti-Inflammatory Agents; Brain; Cannabidiol; Cells, Cultured; Cytokines; Dronabinol; Encephalomyelitis, Autoimmune, Experimental; Female; Leukocytes, Mononuclear; Mice, Inbred C57BL; Mice, Knockout; MicroRNAs; Multiple Sclerosis; Signal Transduction; Spinal Cord; Spleen | 2019 |
Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.
Topics: Animals; Cannabidiol; Cannabinoids; Cannabis; Cytokines; Disease Models, Animal; Dronabinol; Dysbiosis; Encephalomyelitis, Autoimmune, Experimental; Female; Gastrointestinal Microbiome; Inflammation; Interferon-gamma; Interleukin-17; Mice; Mice, Inbred C57BL; Multiple Sclerosis; RNA, Ribosomal, 16S | 2019 |
Cannabinoids decrease the th17 inflammatory autoimmune phenotype.
Topics: Animals; Antigen-Presenting Cells; Cannabidiol; Cell Line; Coculture Techniques; Dronabinol; Encephalomyelitis, Autoimmune, Experimental; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Inflammation; Interferon-gamma; Interleukin-17; Mice, Inbred C57BL; Myelin-Oligodendrocyte Glycoprotein; Peptide Fragments; Phenotype; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Th17 Cells; Tumor Necrosis Factor-alpha | 2013 |
The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.
Topics: Animals; Cannabidiol; Cannabinoid Receptor Modulators; Dronabinol; Drug Combinations; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental; Female; Mice, Inbred C57BL; Neuroprotective Agents; Photomicrography; Piperidines; Plant Extracts; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Spinal Cord | 2015 |
Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis.
Topics: Animals; Antigens, CD; Corpus Striatum; Dendrites; Disease Models, Animal; Dronabinol; Encephalomyelitis, Autoimmune, Experimental; Female; Glutamic Acid; Glycoproteins; In Vitro Techniques; Mice; Mice, Inbred C57BL; Movement Disorders; Myelin-Oligodendrocyte Glycoprotein; Neurons; Neuroprotective Agents; Patch-Clamp Techniques; Peptide Fragments; Physical Conditioning, Animal; Silver Staining; Statistics, Nonparametric; Synapses; Synaptic Potentials | 2009 |
Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Amidohydrolases; Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Corpus Striatum; Dizocilpine Maleate; Dronabinol; Encephalomyelitis, Autoimmune, Experimental; Endocannabinoids; Etanercept; Excitatory Postsynaptic Potentials; Female; Glutamic Acid; Immunoglobulin G; Mice; Mice, Inbred C57BL; Mice, Knockout; Nerve Degeneration; Neurons; Polyunsaturated Alkamides; Receptor, Cannabinoid, CB1; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha | 2011 |
The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis.
Topics: Acute Disease; Adult; Animals; Arachidonic Acids; Brain; Cannabinoid Receptor Modulators; Corpus Striatum; Disease Models, Animal; Dronabinol; Electrophysiology; Encephalomyelitis, Autoimmune, Experimental; Endocannabinoids; Female; Glycerides; Humans; Lymphocytes; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Neuroprotective Agents; Patch-Clamp Techniques; Polyunsaturated Alkamides; Synaptic Transmission; Tissue Culture Techniques | 2007 |
Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis.
Topics: Acute Disease; Animals; Brain; Dose-Response Relationship, Drug; Dronabinol; Encephalomyelitis, Autoimmune, Experimental; Female; Injections, Intraperitoneal; Injections, Intravenous; Multiple Sclerosis; Neuroprotective Agents; Rats; Rats, Inbred Lew; Recurrence; Spinal Cord; Time Factors; Treatment Outcome | 2000 |
Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis.
Topics: Animals; Dronabinol; Drug Administration Schedule; Encephalomyelitis, Autoimmune, Experimental; Guinea Pigs; Immunosuppressive Agents; Pharmaceutical Vehicles; Rats; Rats, Inbred Lew; Spinal Cord | 1989 |